Your session is about to expire
← Back to Search
Sasanlimab for Bladder Cancer (CREST Trial)
CREST Trial Summary
This trial is testing the safety and effects of sasanlimab in people with early stage bladder cancer that is high risk or has been previously treated with BCG.
CREST Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCREST Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CREST Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My bladder cancer is high-risk, not invasive, and didn't respond to BCG therapy.My cancer has spread beyond the bladder lining or is in advanced stages.I have previously received immunotherapy targeting PD-1, PD-L1, PD-L2, or CTLA-4.I had all my bladder tumors surgically removed recently.I have previously been treated with immune-stimulating drugs like IL-2 or interferon.I have had radiation therapy targeting my bladder.My bladder cancer is mainly transitional cell type and considered high risk.I haven't had chemotherapy or immunotherapy since my last bladder tumor surgery.I received BCG therapy for bladder cancer within the last 2 years.I cannot or have chosen not to undergo major bladder surgery.
- Group 1: PF-06801591 + BCG induction only
- Group 2: BCG induction and maintenance
- Group 3: PF-06801591 + BCG induction and maintenance
- Group 4: BCG Unresponsive NMIBC
- Group 5: BCG Unresponsive CIS
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What does the literature say about the potential risks of PF-06801591?
"PF-06801591's safety is estimated to be a 3. This is due to the fact that this clinical trial is in Phase 3, which suggests that there is both efficacy data and multiple rounds of safety data available."
Are people still welcome to sign up and participate in this research?
"Right now, this clinical trial needs participants. The first posting was on December 30th 2019 with the most recent update being October 17th 2020."
Can you tell me how many medical facilities are testing this new treatment?
"Presently, this research is being conducted at UPMC Urology in Pittsburgh, Pennsylvania; University of Minnesota Medical Center, Fairview IDS Pharmacy in Columbia, Missouri; and University of Missouri - Ellis Fischel Cancer Center in Oklahoma City, Oklahoma. In addition to these locations, the study is also running out of 14 other sites."
Share this study with friends
Copy Link
Messenger